BACKGROUND: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. METHODS: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. RESULTS: As compared with patients with 0-1 metabolic features, patients with 3-5 features showed lower percentage of HCC diagnosis on surveillance (P = .021), larger tumours (P = .038), better liver function (higher percentage of Child-Pugh class A [P = .007] and MELD < 10 [P = .003]), higher percentage of metastasis (P = .024) and lower percentage of portal vein thrombosis (P = .010). The BCLC stage and treatment options were similar among the 3 groups, with the exception of a less frequent access to loco-regional therapies for BCLC stage B patients with 3-5 features (P = .012). Overall survival and survival according to BCLC stage and/or treatment did not significantly differ among the 3 groups. Only using a probabilistic sensitivity analysis, diabetic patients showed a lower survival (P = .046). MELD score, HCC morphology, nodule size, BCLC stage, portal vein thrombosis and metastasis were independent predictors of lead-time adjusted survival. CONCLUSIONS: Our "real world" study suggests that metabolic disorders shape the clinical presentation of HCC but do not seem to play a major role in setting patient survival.

Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, patients with 3-5 features showed lower percentage of HCC diagnosis on surveillance (P =.021), larger tumours (P =.038), better liver function (higher percentage of Child-Pugh class A [P =.007] and MELD < 10 [P =.003]), higher percentage of metastasis (P =.024) and lower percentage of portal vein thrombosis (P =.010). The BCLC stage and treatment options were similar among the 3 groups, with the exception of a less frequent access to loco-regional therapies for BCLC stage B patients with 3-5 features (P =.012). Overall survival and survival according to BCLC stage and/or treatment did not significantly differ among the 3 groups. Only using a probabilistic sensitivity analysis, diabetic patients showed a lower survival (P =.046). MELD score, HCC morphology, nodule size, BCLC stage, portal vein thrombosis and metastasis were independent predictors of lead-time adjusted survival. Conclusions: Our “real world” study suggests that metabolic disorders shape the clinical presentation of HCC but do not seem to play a major role in setting patient survival.

Metabolic disorders across hepatocellular carcinoma in Italy / Morisco, F.; Guarino, M.; Valvano, M. R.; Auriemma, F.; Farinati, F.; Giannini, E. G.; Ciccarese, F.; Tovoli, F.; Rapaccini, G. L.; Di Marco, M.; Caturelli, E.; Zoli, M.; Borzio, F.; Sacco, R.; Cabibbo, G.; Felder, M.; Benvengu, L.; Gasbarrini, A.; Svegliati Baroni, G.; Foschi, F. G.; Biasini, E.; Masotto, A.; Virdone, R.; Marra, F.; Caporaso, N.; Trevisani, F.; Sessa, A.; Marafatto, F.; Peserico, G.; Pozzan, C.; Brunacci, M.; Moscatelli, A.; Pellegatta, G.; Savarino, V.; Del Poggio, P.; Olmi, S.; de Matthaeis, N.; Balsamo, C.; Vavassori, E.; Roselli, P.; Lauria, V.; Pelecca, G.; Mismas, V.; Rossi, M.; Attardo, S.; Cavani, G.; Mega, A.; Rinninella, E.; Ortolani, A.; Bevilacqua, V.; Chiara Dall'Aglio, A.; Ercolani, G.; Fiorini, E.; Casadei Gardini, A.; Lanzi, A.; Mirici Cappa, F.; Missale, G.; Porro, E.; Marchetti, F.; Valerio, M.; Affronti, A.; Orlando, E.; Rosa Barcellona, M.; Aburas, S.; Dragoni, G.; Campani, C.; Biselli, M.; Bucci, L.; Caraceni, P.; Cucchetti, A.; Domenicali, M.; Garuti, F.; Gramenzi, A.; Magalotti, D.; Serra, C.; Granito, A.; Negrini, G.; Napoli, L.; Piscaglia, F.. - In: LIVER INTERNATIONAL. - ISSN 1478-3223. - 38:11(2018), pp. 2028-2039. [10.1111/liv.13877]

Metabolic disorders across hepatocellular carcinoma in Italy

Guarino M.;Farinati F.;Di Marco M.;Sessa A.;Balsamo C.;Mega A.;Fiorini E.;Casadei Gardini A.;Lanzi A.;Marchetti F.;Orlando E.;Garuti F.;Magalotti D.;Negrini G.;
2018

Abstract

BACKGROUND: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. METHODS: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. RESULTS: As compared with patients with 0-1 metabolic features, patients with 3-5 features showed lower percentage of HCC diagnosis on surveillance (P = .021), larger tumours (P = .038), better liver function (higher percentage of Child-Pugh class A [P = .007] and MELD < 10 [P = .003]), higher percentage of metastasis (P = .024) and lower percentage of portal vein thrombosis (P = .010). The BCLC stage and treatment options were similar among the 3 groups, with the exception of a less frequent access to loco-regional therapies for BCLC stage B patients with 3-5 features (P = .012). Overall survival and survival according to BCLC stage and/or treatment did not significantly differ among the 3 groups. Only using a probabilistic sensitivity analysis, diabetic patients showed a lower survival (P = .046). MELD score, HCC morphology, nodule size, BCLC stage, portal vein thrombosis and metastasis were independent predictors of lead-time adjusted survival. CONCLUSIONS: Our "real world" study suggests that metabolic disorders shape the clinical presentation of HCC but do not seem to play a major role in setting patient survival.
38
11
2028
2039
Metabolic disorders across hepatocellular carcinoma in Italy / Morisco, F.; Guarino, M.; Valvano, M. R.; Auriemma, F.; Farinati, F.; Giannini, E. G.; Ciccarese, F.; Tovoli, F.; Rapaccini, G. L.; Di Marco, M.; Caturelli, E.; Zoli, M.; Borzio, F.; Sacco, R.; Cabibbo, G.; Felder, M.; Benvengu, L.; Gasbarrini, A.; Svegliati Baroni, G.; Foschi, F. G.; Biasini, E.; Masotto, A.; Virdone, R.; Marra, F.; Caporaso, N.; Trevisani, F.; Sessa, A.; Marafatto, F.; Peserico, G.; Pozzan, C.; Brunacci, M.; Moscatelli, A.; Pellegatta, G.; Savarino, V.; Del Poggio, P.; Olmi, S.; de Matthaeis, N.; Balsamo, C.; Vavassori, E.; Roselli, P.; Lauria, V.; Pelecca, G.; Mismas, V.; Rossi, M.; Attardo, S.; Cavani, G.; Mega, A.; Rinninella, E.; Ortolani, A.; Bevilacqua, V.; Chiara Dall'Aglio, A.; Ercolani, G.; Fiorini, E.; Casadei Gardini, A.; Lanzi, A.; Mirici Cappa, F.; Missale, G.; Porro, E.; Marchetti, F.; Valerio, M.; Affronti, A.; Orlando, E.; Rosa Barcellona, M.; Aburas, S.; Dragoni, G.; Campani, C.; Biselli, M.; Bucci, L.; Caraceni, P.; Cucchetti, A.; Domenicali, M.; Garuti, F.; Gramenzi, A.; Magalotti, D.; Serra, C.; Granito, A.; Negrini, G.; Napoli, L.; Piscaglia, F.. - In: LIVER INTERNATIONAL. - ISSN 1478-3223. - 38:11(2018), pp. 2028-2039. [10.1111/liv.13877]
Morisco, F.; Guarino, M.; Valvano, M. R.; Auriemma, F.; Farinati, F.; Giannini, E. G.; Ciccarese, F.; Tovoli, F.; Rapaccini, G. L.; Di Marco, M.; Caturelli, E.; Zoli, M.; Borzio, F.; Sacco, R.; Cabibbo, G.; Felder, M.; Benvengu, L.; Gasbarrini, A.; Svegliati Baroni, G.; Foschi, F. G.; Biasini, E.; Masotto, A.; Virdone, R.; Marra, F.; Caporaso, N.; Trevisani, F.; Sessa, A.; Marafatto, F.; Peserico, G.; Pozzan, C.; Brunacci, M.; Moscatelli, A.; Pellegatta, G.; Savarino, V.; Del Poggio, P.; Olmi, S.; de Matthaeis, N.; Balsamo, C.; Vavassori, E.; Roselli, P.; Lauria, V.; Pelecca, G.; Mismas, V.; Rossi, M.; Attardo, S.; Cavani, G.; Mega, A.; Rinninella, E.; Ortolani, A.; Bevilacqua, V.; Chiara Dall'Aglio, A.; Ercolani, G.; Fiorini, E.; Casadei Gardini, A.; Lanzi, A.; Mirici Cappa, F.; Missale, G.; Porro, E.; Marchetti, F.; Valerio, M.; Affronti, A.; Orlando, E.; Rosa Barcellona, M.; Aburas, S.; Dragoni, G.; Campani, C.; Biselli, M.; Bucci, L.; Caraceni, P.; Cucchetti, A.; Domenicali, M.; Garuti, F.; Gramenzi, A.; Magalotti, D.; Serra, C.; Granito, A.; Negrini, G.; Napoli, L.; Piscaglia, F.
File in questo prodotto:
File Dimensione Formato  
morisco2018.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 832.72 kB
Formato Adobe PDF
832.72 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1177528
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact